Citi sees positive read-through to Lilly shares on FDA GLP-1 statement
Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s ...
Ever-Growing USA on MSN12h
Retratutide: Eli Lilly’s Groundbreaking Drug Poised to Transform Obesity and Diabetes Treatment
In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...
Fierce Pharma3d
Senators expand probe of Pfizer, Lilly DTC platforms to include telehealth provider partners
In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...
The Walrus4d
Men Are Playing “Russian Roulette” with Black-Market Sex Drugs
Among these was a product called VIP Go Rhino Gold 69K from a sex shop in Quebec City, Quebec; Alien 2 Power Platinum 11000 ...
STAT5d
Telehealth platforms in senators’ crosshairs over relationship with Eli Lilly, Pfizer
Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
AOL17d
Eli Lilly Doubles Capital Spending On US Drug Manufacturing With $50 Billion Target (CORRECTED)
At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical ...
devdiscourse18d
Eli Lilly's $27 Billion US Expansion: A Boost to Domestic Drug Manufacturing
Eli Lilly plans a $27 billion investment to establish four manufacturing plants in the U.S., anticipated to generate 3,000 jobs for skilled workers and 10,000 construction jobs. The move aligns with ...
New York Post19d
Eli Lilly plans to invest $27B to build four new US plants as tariffs loom
Eli Lilly said Wednesday it will invest $27 billion to build four new manufacturing plants in the United States as the pharmaceutical giant grapples with the threat of drug import duties from the ...